news
GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director
6 October 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015...
List view / Grid view
GlaxoSmithKline (GSK)
news
GlaxoSmithKline plc appoints Sir Philip Hampton to the Board of Directors
25 September 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015 and will become Deputy Chairman with effect from 1 April 2015...
news
GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa
10 September 2014 | By GlaxoSmithKline
GSK announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases in Africa, as part of GSK’s Africa NCD Open Lab initiative...
news
GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions
8 September 2014 | By GlaxoSmithKline
GSK presented data at the European Respiratory Society Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an inhaled corticosteroid containing regimen...
article
Can HPLC assay methods really be considered quality critical tests?
Analytical method specificity is assessed using ICH (International Conference on Harmonisation) Q2 (2005). Although, certain methods are not specific enough for their intended purposes, they may have other advantages. Both titrimetric and UV (Ultra-violet spectroscopy) assays are non-specific, but have superior precision (ca. 0.1-0.5% RSD (Residual Standard Deviation)) compared with…
news
Ebola vaccine trials fast-tracked by international consortium
28 August 2014 | By GlaxoSmithKline
Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine...
news
GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)
27 August 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy...
news
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
26 August 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the US Food and Drug Administration has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection...
news
FDA approves Flonase allergy relief for sale over-the-counter in the United States
25 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray)...
news
ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir
22 July 2014 | By GlaxoSmithKline
...with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1.
news
Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib
18 July 2014 | By GlaxoSmithKline
...phase III BRAF V600-mutant metastatic melanoma study stopped early.
news
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
news
Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD
4 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases...
article
What does quality mean to you?
An effective quality risk management (QRM) process ensures proactive identification and control of potential issues that may arise during development and commercialisation. Where quality is defined as the degree to which a set of intrinsic properties of a drug product, its underpinning manufacturing process, and any supporting processes fulfils the…
news
GSK statement on UK Government-initiated review of antibiotic resistance
3 July 2014 | By GlaxoSmithKline
“We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance..."
